Insulin Pharmacokinetics

No abstract is available for this paper.

• Publication year

  1984

• Venue

  Diabetes Care

• Publication date

  1984-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.2337/diacare.7.2.188PMID 6376015
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The absorption of soluble insulin correlated to the diabetic state.

  2009cited by this paper
• Absorption of injected insulin. A clinical-pharmacological study.

  2009cited by this paper
• The biological properties of human insulin. Subcutaneous absorption, receptor binding and the clinical effect in diabetics assessed by a new statistical method.

  2009cited by this paper
• Absorption of NPH-insulin from subcutaneous tissue: a methodological study in pigs.

  2009cited by this paper
• Absorption of soluble and isophane semi-synthetic human and porcine insulin in insulin-dependent diabetic subjects.

  1984cited by this paper
• Clinical Factors Influencing the Absorption of 125I-NPH Insulin in Diabetic Patients

  1983cited by this paper
• Subcutaneous aprotinin causes local hyperaemia

  1983cited by this paper
• Pharmacokinetics of continuous subcutaneous insulin infusion

  1983cited by this paper
• The Pharmacokinetics of Insulin After Continuous Subcutaneous Infusion or Bolus Subcutaneous Injection in Diabetic Patients

  1983cited by this paper
• Change to U-100 insulin does not appear to affect insulin absorption.

  1983cited by this paper
• Improved Serum Insulin Profiles in Diabetic Individuals Who Massaged Their Insulin Injection Sites

  1983cited by this paper
• Subcutaneous use of regular human insulin (Novo): pharmacokinetics and continuous insulin infusion therapy.

  1983cited by this paper
• Absorption and Miscibility of Regular Porcine Insulin After Subcutaneous Injection of Insulin-treated Diabetic Patients

  1983cited by this paper
• Importance of Timing of Preprandial Subcutaneous Insulin Administration in the Management of Diabetes Mellitus

  1983cited by this paper
• Absorption rates of subcutaneously injected insulin in the dog as calculated from the plasma insulin levels by means of a simple mathematical model

  1983cited by this paper
• Overnight Metabolic Control with Pulsed Intermittent Versus Continuous Subcutaneous Insulin Infusion

  1983cited by this paper
• Insulin absorption from the abdomen and the thigh in healthy subjects during rest and exercise: Blood glucose, plasma insulin, growth hormone, adrenaline and noradrenaline levels

  1982cited by this paper
• Effect of bicycle exercise on insulin absorption and subcutaneous blood flow in the normal subject.

  1982cited by this paper
• Absorption of isophane (NPH) insulin and its clinical implications.

  1982cited by this paper
• Absorption Kinetics and Biologic Effects of Subcutaneously Injected Insulin Preparations

  1982cited by this paper
• Biotelemetric detection of the disappearance of subcutaneously injected 125I-NPH insulin.

  1982cited by this paper
• Smoking reduces insulin absorption from subcutaneous tissue.

  1982cited by this paper
• Evidence for insulin degradation by muscle and fat tissue in an insulin resistant diabetic patient

  1982cited by this paper
• Development of the Biostator Glucose clamping algorithm.

  1982cited by this paper
• Kinetics of subcutaneous NPH insulin in diabetics

  1982cited by this paper
• The accuracy of drawing up insulin by insulin treated diabetics.

  1982cited by this paper
• Pharmacokinetics of Biosynthetic Human Insulin and Characteristics of Its Effect

  1981cited by this paper
• Comparison of Biosynthetic Human Insulin and Pork Insulin in the Gerritzen Test

  1981cited by this paper
• A rise in ambient temperature augments insulin absorption in diabetic patients.

  1981cited by this paper
• Plasma Free Insulin Profiles After Administration of Insulin by Jet and Conventional Syringe Injection

  1981cited by this paper
• Factors Influencing the Absorption, Serum Insulin Concentration, and Blood Glucose Responses After Injections of Regular Insulin and Various Insulin Mixtures

  1981cited by this paper
• Comparative study of subcutaneous, intramuscular, and intravenous administration of human insulin.

  1981cited by this paper
• Do Diabetic Patients Inject Accurate Doses of Insulin?

  1981cited by this paper
• Programming of Insulin Delivery with Meals During Subcutaneous Insulin Infusion

  1981cited by this paper
• Subcutaneous degradation of insulin

  1981cited by this paper
• [Pharmacokinetics of insulin administered intraperitoneal in a bolus form (author's transl)].

  1981cited by this paper
• Diabetes responsive to intravenous but not subcutaneous insulin: effectiveness of aprotinin.

  1981cited by this paper
• Insulin degradation in serum of a patient with apparent insulin resistance.

  1981cited by this paper
• Human insulin: study of safety and efficacy in man.

  1981cited by this paper
• Biologic Activity and Pharmacokinetics of Biosynthetic Human Insulin in the Rat

  1981cited by this paper
• Management of severely brittle diabetes by continuous subcutaneous and intramuscular insulin infusions: evidence for a defect in subcutaneous insulin absorption.

  1981cited by this paper
• Alterations in Insulin Absorption and in Blood Glucose Control associated with Varying Insulin Injection Sites in Diabetic Patients

  1981cited by this paper
• Matched glucose responses to insulin administered subcutaneously and intravenously

  1980cited by this paper
• Control of blood sugar in insulin-dependent diabetes: comparison of an artificial endocrine pancreas, continuous subcutaneous insulin infusion, and intensified conventional insulin therapy.

  1980cited by this paper
• Comparison of 125 I-Insulin and [B1- 3 H-Phenylalanine]- Insulin Degradation by Insulin Protease

  1980cited by this paper
• Sauna-induced acceleration in insulin absorption.

  1980cited by this paper
• Intermediate-acting Insulin Preparations: NPH and Lente

  1980cited by this paper
• The Chemical Characterization of the Products of the Processing of Subcutaneously Injected Insulin

  1980cited by this paper
• Circulating insulin-binding antibodies

  1980cited by this paper
• Alterations in Insulin Absorption and in Blood Glucose Control Associated with Varying Insulin Injection Sites in Diabetic Patients

  1980cited by this paper
• The Effect of Aprotinin on the Absorption of Subcutaneously Injected Regular Insulin in Normal Subjects

  1980cited by this paper
• Resistance against subcutaneous insulin successfully managed with aprotinin.

  1980cited by this paper
• Timing of pre-breakfast insulin injection and postprandial metabolic control in diabetic children

  1980cited by this paper
• Sauna-induced acceleration in insulin absorption from subcutaneous injection site.

  1980cited by this paper
• IMPORTANCE OF INSULIN ABSORPTION, SUBCUTANEOUS BLOOD FLOW, AND RESIDUAL BETA‐CELL FUNCTION IN INSULIN THERAPY

  1980cited by this paper
• Studies on monocomponent insulin. IV. Subcutaneous absorption of insulin from preparations with protracted action.

  1980cited by this paper
• Sauna-induced acceleration in insulin absorption.

  1980cited by this paper
• Variation in125i-insulin absorption and blood glucose concentration

  1979cited by this paper
• Absorption kinetics of subcutaneously injected insulin

  1979cited by this paper
• Accelerated Insulin Degradation: An Alternate Mechanism for Insulin Resistance

  1979cited by this paper
• Insulin Resistance Caused by Massive Degradation of Subcutaneous Insulin

  1979cited by this paper
• Accelerated insulin degradation: an alternate mechanism for insulin resistance.

  1979cited by this paper
• Free insulin, bound insulin, C‐peptide and the metabolic control in juvenile onset diabetics: comparison of C‐peptide secretors and non‐secretors during 24 hours conventional insulin therapy

  1979cited by this paper
• Absorption of Protamine-lnsulin in Diabetic Patients - I. Preparation and Characterization of Protamine-125I-InsuIin

  1979cited by this paper
• Role of residual insulin secretion in protecting against ketoacidosis in insulin-dependent diabetes.

  1979cited by this paper
• Exercise-induced Fall of Blood Glucose in Insulin-treated Diabetics Unrelated to Alteration of Insulin Mobilization

  1979cited by this paper
• Adipose tissue blood flow and insulin disappearance from subcutaneous tissue

  1979cited by this paper
• Pharmacokinetics of Subcutaneously Injected Tritiated Insulin: Effects of Exercise

  1979cited by this paper
• Plasma Insulin and C-Peptide Levels During Continuous Subcutaneous Insulin Infusion

  1979cited by this paper
• A Comparison between Diabetics Receiving a High or Low Daily Insulin Dosage

  1978cited by this paper
• Change of insulin dosage, circulating free and bound insulin and insulin antibodies on transferring diabetics from conventional to highly purified porcine insulin

  1978cited by this paper
• DEFECTIVE ABSORPTION OF INJECTED INSULIN

  1978cited by this paper
• The relationship between circulating free and bound insulin, insulin antibodies, insulin dosage and diabetic control in insulin treated diabetics.

  1978cited by this paper
• Mobilization of subcutaneously injected tritiated insulin in rats: Effects of muscular exercise

  1978cited by this paper
• Effects of leg exercise on insulin absorption in diabetic patients.

  1978cited by this paper
• Glucose-lowering effect of insulin by different routes in obese and lean nonketotic diabetic patients.

  1978cited by this paper
• Insulin-binding antibody: Reaction differences with bovine and porcine insulins

  1978cited by this paper
• Low-dose insulin infusions in diabetic patients with high insulin requirements.

  1978cited by this paper
• Insulin absorption and insulin requirement.

  1978cited by this paper
• Insulin via continuous subcutaneous infusion.

  1978cited by this paper
• Absorption, effectiveness and side effects of highly purified porcine NPH-insulin preparations (Leo®)

  1978cited by this paper
• Determination of Insulin Requirements in Brittle Diabetic Patients by the Artificial Pancreas

  1978cited by this paper
• INSULIN ABSORPTION AND INSULIN REQUIREMENT

  1978cited by this paper
• THE ABSORPTION OF INSULIN

  1977cited by this paper
• Effects of highly purified insulin on dosage requirements.

  1977cited by this paper
• Insulin binding capacity in patients changed from conventional to highly purified insulins

  1977cited by this paper
• Serum free insulin concentrations during the treatment of diabetic coma and precoma with low dose intramuscular insulin

  1977cited by this paper
• Clinical evaluation and preliminary studies on the use of an artificial pancreatic beta cell in juvenile diabetes mellitus.

  1977cited by this paper
• Comparison of the effectiveness of various routes of insulin injection: insulin levels and glucose response in normal subjects.

  1976cited by this paper
• Equilibrium binding studies of insulin antibodies in diabetic subjects.

  1976cited by this paper
• Errors in insulin doses due to the design of insulin syringes.

  1975cited by this paper
• The preparation of a semisynthetic tritiated insulin with a specific radioactivity of up to 20 Curies per millimole.

  1975cited by this paper
• Measurement of antibodies on insulin in serum.

  1974cited by this paper
• A Comparison of Acid Regular and Neutral Regular Insulin: Responses of Normal Fasted Subjects to Varying Doses of Regular Insulin

  1973cited by this paper
• Use of Jet Insulin Injection in Diabetes Mellitus Therapy

  1972cited by this paper
• Subcutaneous and Intramuscular Injection of Drugs

  1971cited by this paper
• The Absorption of an Acid and a Neutral Insulin Solution after Subcutaneous Injection into Different Regions in Diabetic Patients

  1967cited by this paper
• Absorption of 131-I labeled modified insulin

  1967cited by this paper
• Letter to the editor.

  1967cited by this paper
• DISAPPEARANCE OF I-131-LABELED INSULIN FROM PLASMA AS A GUIDE TO MANAGEMENT OF DIABETES.

  1964cited by this paper

• A Mathematical Model for Type 1 Diabetes Regulation Using a Smart Insulin Patch: In Silico Validation Based on Published Rat Data

  2026cites this paper
• Emerging Insulin Analogues: A Glimpse into How Insulin Analogues May Look in the near Future

  2025cites this paper
• Sensitivity analysis for a delay mathematical model: the glucose-insulin model

  2025cites this paper
• Adaptive Multi-modal Fusion with Temporal Attention for Uncertainty-aware Closed-loop Insulin Delivery Control

  2025cites this paper
• Insulin Therapy

  2025cites this paper
• Performance of an individualized, subcutaneous, basal-bolus insulin regimen for the management of prednisolone-associated hyperglycemia in hospitalized patients: a proof-of-concept study

  2025cites this paper
• Equivalent Electrical Circuit Approach to Enhance a Transducer for Insulin Bioavailability Assessment

  2024cites this paper
• IGF2BP2 and IGFBP3 Genotypes, Haplotypes, and Genetic Models Studies in Polycystic Ovary Syndrome

  2024cites this paper
• Key indices of glycaemic variability for application in diabetes clinical practice.

  2023cites this paper
• Centenary of Insulin Therapy: A Review.

  2023cites this paper
• Peptide Inhibitors of Insulin Fibrillation: Current and Future Challenges

  2023cites this paper
• Global Deep Forecasting with Patient-Specific Pharmacokinetics

  2023cites this paper
• The hidden obstacles to intranasal insulin delivery: A narrative review

  2023cites this paper
• A Reproducible Bioimpedance Transducer for Insulin Noninvasive Measurement

  2023cites this paper
• Insulin murder and the case of Colin Norris.

  2023cites this paper
• Antibody-Mediated Inhibition of Insulin-Degrading Enzyme Improves Insulin Activity in a Diabetic Mouse Model

  2022cites this paper
• A Conversation on an Effective, Straightforward, Quantitative Approach to the Outpatient Use of Insulin.

  2022cites this paper
• One-hundred year evolution of prandial insulin preparations: from animal pancreas extracts to rapid-ACTING analogs.

  2021cites this paper
• Interindividual Variability in the Pharmacodynamic and Pharmacokinetic Characteristics of Recombinant Human Insulin and Insulin Aspart.

  2021cites this paper
• L'épopée des insulines des années 1930 aux années 1980

  2021cites this paper
• Si l'ère des insulines semi-synthétiques et biosynthétiques nous était contée

  2021cites this paper
• Biological drug therapy for ocular angiogenesis: Anti‐VEGF agents and novel strategies based on nanotechnology

  2021cites this paper
• Artificial Pancreas Control Strategies Used for Type 1 Diabetes Control and Treatment: A Comprehensive Analysis

  2020cites this paper
• Pharmacokinetics of Faster and Standard Insulin Aspart During Fully Closed-Loop Insulin Delivery in Type 2 Diabetes

  2020cites this paper
• A Review on Insulin Formulations for Diabetes Mellitus Therapy

  2020cites this paper
• Comparison between a flash glucose monitoring system and a portable blood glucose meter for monitoring dogs with diabetes mellitus

  2020cites this paper
• Cerebro‐renal interaction and stroke

  2020cites this paper
• A Brief Overview of the Oral Delivery of Insulin as an Alternative to the Parenteral Delivery.

  2020cites this paper
• An observational, multicentre study on different insulin glargine U100 titration algorithms used in patients with type 2 diabetes in daily medical practice in Adriatic countries: The ADRESA study.

  2019cites this paper
• Thérapeutique des désordres glycémiques

  2019cites this paper
• Clinical challenges with excipients in insulin formulations and role of concentrated insulin

  2019cites this paper
• Delayed Response to U-500 Regular Insulin

  2018cites this paper
• Factors Affecting the Absorption of Subcutaneously Administered Insulin: Effect on Variability

  2018influential citation
• Octreotide for the treatment of intentional insulin aspart overdose in a non-diabetic patient.

  2018cites this paper
• Oral insulin delivery: existing barriers and current counter‐strategies

  2018cites this paper
• Combination of coating and injectable hydrogel depot to improve the sustained delivery of insulin

  2018cites this paper
• MECHANISMS IN ENDOCRINOLOGY: Aging and anti-aging: a Combo-Endocrinology overview.

  2017cites this paper
• DEVELOPMENT AND EVALUATION OF FILMS BASED ON MICROEMULSIFIED INSULIN FOR BUCCAL DELIVERY USING MAISINE

  2017cites this paper
• Aging and Anti-aging Endocrinology : A Combo Overview

  2017cites this paper
• Current trend in drug delivery considerations for subcutaneous insulin depots to treat diabetes.

  2017cites this paper
• Detailed Analysis of Insulin Absorption Variability and the Tissue Response to Continuous Subcutaneous Insulin Infusion Catheter Implantation in Swine

  2017cites this paper
• Mathematical Model of Glucose-Insulin Metabolism Considering Meal Absorption Rate and Model-based Blood Glucose Control for Prandial State in Type 1 Diabetes

  2016cites this paper
• Converting U-500 regular insulin to insulin detemir and insulin lispro in a patient undergoing dietary changes in preparation for bariatric surgery.

  2016cites this paper
• The Effect of Canagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, on Glycemic End Points Assessed by Continuous Glucose Monitoring and Patient-Reported Outcomes Among People With Type 1 Diabetes

  2016cites this paper
• Protein-targeted corona phase molecular recognition

  2016cites this paper
• Pharmacometric Models of Glucose Homeostasis in Healthy Subjects and Diabetes Patients

  2016cites this paper
• Lipohypertrophy - The Neglected Area of Concern in the much Talked about Diabetes

  2015influential citation
• Intensive Insulin Titration with Insulin Glargine in Insulin-Naive Type 2 Diabetic Patients in Turkey: LANTIT Study

  2015cites this paper
• The Impact of Technology on Current Diabetes Management.

  2015cites this paper
• Plasma insulin profiles after subcutaneous injection: how close can we get to physiology in people with diabetes?

  2015cites this paper
• [Use of human insulin analogues in young patients with type 1 diabetes mellitus: Results of the RESULT observational program on the use of insulin glargine (Lantus) in combination with insulin glulisine (Apidra) as a basal-bolus regimen].

  2015cites this paper
• Pharmacokinetics and Pharmacodynamics of NPH Insulin in Type 1 Diabetes: The Importance of Appropriate Resuspension Before Subcutaneous Injection

  2015cites this paper
• Optimal glucose management in the perioperative period.

  2015cites this paper
• Impact of Bromocriptine-QR Therapy on Glycemic Control and Daily Insulin Requirement in Type 2 Diabetes Mellitus Subjects Whose Dysglycemia Is Poorly Controlled on High-Dose Insulin: A Pilot Study

  2015cites this paper
• A Pharmacokinetic Model of a Tissue Implantable Insulin Sensor

  2015cites this paper
• Intestinal uptake of insulin nanoparticles: facts or myths?

  2014cites this paper
• Association between Temperature and Emergency Room Visits for Cardiorespiratory Diseases, Metabolic Syndrome-Related Diseases, and Accidents in Metropolitan Taipei

  2014cites this paper
• [Evaluation of the DIABOBHU Observational Study].

  2014cites this paper
• Peripartum Management of Glycemia in Women With Type 1 Diabetes

  2014cites this paper
• Can Glucose Be Monitored Accurately at the Site of Subcutaneous Insulin Delivery?

  2014cites this paper
• Insulin therapy for type 2 diabetes mellitus.

  2014cites this paper
• A Randomized Clinical Trial of Insulin Glargine and Aspart, Compared to NPH and Regular Insulin in Children with Type 1 Diabetes Mellitus

  2014cites this paper
• A Control-Relevant Model of Subcutaneous Insulin Absorption

  2014cites this paper
• Modeling and Prediction in Diabetes Physiology

  2013cites this paper
• Comparison of glucose fluctuations between day- and night-time measured using a continuous glucose monitoring system in diabetic dogs.

  2013cites this paper
• The Effect of Regular Human Insulin and Glulisine Insulin on Blood Glucosa Concentration in Diabetic Nephropathy Patients with Hyperglycemia

  2013cites this paper
• The peripartum management of glycaemia in women with Type 1 diabetes Running title: Type 1 diabetes in the peripartum

  2013cites this paper
• Future of newer basal insulin

  2013cites this paper
• Injectable and biodegradable thermosensitive hydrogels loaded with PHBHHx nanoparticles for the sustained and controlled release of insulin.

  2013cites this paper
• The use of U‐500 regular insulin in the management of patients with obesity and insulin resistance

  2013cites this paper
• Better Glycemic Control and Weight Loss With the Novel Long-Acting Basal Insulin LY2605541 Compared With Insulin Glargine in Type 1 Diabetes

  2013cites this paper
• PTH(1‐84) replacement therapy in hypoparathyroidism: A randomized controlled trial on pharmacokinetic and dynamic effects after 6 months of treatment

  2013cites this paper
• Basal insulin analogs: from pathophysiology to therapy. What we see, know, and try to comprehend?

  2013cites this paper
• Management of hyperglycemia in patients with chronic kidney disease.

  2013cites this paper
• Decreased Subcutaneous Bioavailability of an Oxyntomodulin Analog in a Controlled Release Formulation could be Caused by Skin Metabolism in Rats

  2012cites this paper
• Clinical Use of U-500 Regular Insulin: Review and Meta-Analysis

  2012cites this paper
• Polyelectrolyte complex nanoparticles of amino poly(glycerol methacrylate)s and insulin.

  2012cites this paper
• Nanomedicine Current Trends in Diabetes Management

  2012cites this paper
• Insulins: past, present, and future.

  2012cites this paper
• Response to Dr. Deluzio's Letter to the Editor

  2012cites this paper
• Strategies Toward the Improved Oral Delivery of Insulin Nanoparticles via Gastrointestinal Uptake and Translocation

  2012cites this paper
• A Comparison of Pharmacokinetics and Pharmacodynamics of Insulin Aspart, Biphasic Insulin Aspart 70, Biphasic Insulin Aspart 50, and Human Insulin: A Randomized, Quadruple Crossover Study

  2012cites this paper
• Pharmacokinetics of subcutaneous depot medroxyprogesterone acetate injected in the upper arm.

  2012cites this paper
• Management and treatment of diabetes mellitus.

  2012cites this paper
• Pharmacokinetics and pharmacodynamics of protamine zinc recombinant human insulin in healthy dogs.

  2012cites this paper
• A retrospective study comparing neutral protamine hagedorn insulin with glargine as basal therapy in prednisone-associated diabetes mellitus in hospitalized patients.

  2012cites this paper
• Management of Diabetes Mellitus: Shifting Paradigm

  2012cites this paper
• Efficacy of long-acting insulin analog insulin glargine at high dosage for basal-bolus insulin therapy in patients with type 2 diabetes.

  2012cites this paper
• Clinical experience with U500 insulin: risks and benefits.

  2012cites this paper
• Evolution of Insulin Development: Focus on Key Parameters

  2012cites this paper
• Glycemic variability in type 2 diabetes mellitus: oxidative stress and macrovascular complications.

  2012cites this paper
• Interindividual and Intraindividual Variations in Postprandial Glycemia Peak Time Complicate Precise Recommendations for Self-Monitoring of Glucose in Persons with Type 1 Diabetes Mellitus

  2012cites this paper
• Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady‐state conditions in type 1 diabetes

  2012cites this paper
• Insulin pump therapy guidelines for China (July 2010)

  2012cites this paper
• Development of AIDA v4.3b Diabetes Simulator: Technical Upgrade to Support Incorporation of Lispro, Aspart, and Glargine Insulin Analogues

  2011cites this paper
• A review of the prospects for polymeric nanoparticle platforms in oral insulin delivery.

  2011cites this paper
• Pharmacokinetics and Pharmacodynamics of High-Dose Human Regular U-500 Insulin Versus Human Regular U-100 Insulin in Healthy Obese Subjects

  2011cites this paper
• Nanomedicine for diabetes treatment.

  2011cites this paper
• Basal Insulin: Physiology, Pharmacology, and Clinical Implications

  2011cites this paper
• Enhanced Absorption of Nasulin™, an Ultrarapid-Acting Intranasal Insulin Formulation, Using Single Nostril Administration in Normal Subjects

  2011cites this paper